The $25M Breast Cancer Research Fight That Just Hit Parliament

Jan de Vries · 2026-09-08

Here's a story that's been quietly building momentum, and it finally reached the floor of Parliament this week. A group of determined campaigners has taken their fight for dedicated breast cancer research funding straight to the top, and the timing couldn't be more critical. ### The Core Issue at Hand At the heart of this push is a demand for $25 million in dedicated research funding for invasive lobular breast cancer (ILC). If you haven't heard of ILC, you're not alone—and that's exactly the problem. Unlike the more common invasive ductal carcinoma, ILC is notoriously tricky to detect on standard mammograms. It doesn't always form a lump; instead, it spreads like a web through breast tissue, which means it often goes unnoticed until it's at a more advanced stage. Campaigners have been vocal about the fact that ILC accounts for roughly 10 to 15 percent of all breast cancer cases, yet it receives a fraction of the research attention it deserves. That lack of focus has real consequences for patients who are diagnosed later and face fewer targeted treatment options. ### Why This Moment Matters The campaign chose to target Andy Burnham during Prime Minister's Questions (PMQs), which is a strategic move. PMQs is one of the few times when the nation's political leaders are directly accountable to public questioning, and it draws massive media coverage. By bringing this issue there, the campaigners ensured it couldn't be ignored. Burnham, who has been a vocal advocate for healthcare reform in the past, now finds himself in the hot seat. The pressure is on for him to publicly back this funding initiative, and the campaigners are making it clear that words alone won't be enough. ### The Real-World Impact of Underfunding Let's talk about what underfunding actually means for patients. Without dedicated research, we're essentially flying blind when it comes to: - **Early detection methods** that can reliably catch ILC before it spreads - **Targeted treatments** that address the unique biology of lobular cancer cells - **Clinical trials** that include ILC patients as a distinct group rather than lumping them in with all breast cancers - **Survivorship research** that looks at the long-term effects of treatment on ILC patients Every year that passes without dedicated funding is a year where women and men with ILC are being diagnosed later, treated less effectively, and surviving less often. That's not a hypothetical scenario—that's the current reality. ### What Happens Next The campaigners aren't backing down. They've made it clear that this is just the beginning of a sustained effort to secure this funding. The ball is now in the political court, and the question is whether Burnham and his colleagues will step up. > "We're not asking for a favor. We're asking for fairness in research funding. Every cancer patient deserves the same chance at early detection and effective treatment, regardless of the subtype they're fighting." — A campaign spokesperson ### Why You Should Care Even if you're not directly affected by breast cancer, this fight is a bellwether for how we prioritize medical research. If a cancer that affects one in ten breast cancer patients can be systematically underfunded, what else is slipping through the cracks? This is about more than one disease or one funding request. It's about whether our research infrastructure is truly serving everyone who needs it, or just the loudest voices and most common diagnoses. The next few weeks will be telling. Will this $25 million become a reality, or will it become another broken promise? The campaigners have done their part by bringing it to the national stage. Now, it's up to the politicians to show they were listening.